Cimplrx Co. Ltd. and Dong Wha Pharmaceutical Co. Ltd. have discovered new carboxamide derivatives acting as interleukin-1 receptor-associated kinase 4 (IRAK-4) and/or IRAK-1 inhibitors. As such, they are potentially useful for the treatment of cancer, autoimmune disease and inflammatory disorders.